BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 36508413)

  • 1. Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.
    Ilg MM; Lapthorn AR; Ralph DJ; Cellek S
    PLoS One; 2022; 17(12):e0277646. PubMed ID: 36508413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.
    Ilg MM; Mateus M; Stebbeds WJ; Milenkovic U; Christopher N; Muneer A; Albersen M; Ralph DJ; Cellek S
    Eur Urol; 2019 Feb; 75(2):329-340. PubMed ID: 30344087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease.
    Ilg MM; Stafford SJ; Mateus M; Bustin SA; Carpenter MJ; Muneer A; Bivalacqua TJ; Ralph DJ; Cellek S
    J Sex Med; 2020 Oct; 17(10):1848-1864. PubMed ID: 32771352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease.
    Mateus M; Ilg MM; Stebbeds WJ; Christopher N; Muneer A; Ralph DJ; Cellek S
    J Sex Med; 2018 Jul; 15(7):947-957. PubMed ID: 29891411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in Peyronie's-like plaque size using a vacuum erection device in a rat model of Peyronie's disease via the TGF-β/SMAD signalling pathway.
    Li J; Wang S; Qin F; Zhu M; You X; Wu C; Fu F; Yuan J
    Andrologia; 2018 Sep; 50(7):e13051. PubMed ID: 29806152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Peyronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation.
    Milenkovic U; Ilg MM; Zuccato C; Ramazani Y; De Ridder D; Albersen M
    BJU Int; 2019 Apr; 123(4):703-715. PubMed ID: 30536599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins synergize with phosphodiesterase type 5 inhibitors but not with selective estrogen receptor modulators to prevent myofibroblast transformation in an in vitro model of Peyronie's disease.
    Ilg MM; Ralph DJ; Cellek S
    J Sex Med; 2023 Jun; 20(7):925-934. PubMed ID: 37082866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.
    Gelfand RA; Vernet D; Kovanecz I; Rajfer J; Gonzalez-Cadavid NF
    J Sex Med; 2015 Feb; 12(2):313-27. PubMed ID: 25496134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-β1 induces formation of TSG-6-enriched extracellular vesicles in fibroblasts which can prevent myofibroblast transformation by modulating Erk1/2 phosphorylation.
    Ilg MM; Bustin SA; Ralph DJ; Cellek S
    Sci Rep; 2024 May; 14(1):12389. PubMed ID: 38811625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease.
    Davila HH; Ferrini MG; Rajfer J; Gonzalez-Cadavid NF
    BJU Int; 2003 Jun; 91(9):830-8. PubMed ID: 12780843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor (TGF)-β type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque.
    Piao S; Choi MJ; Tumurbaatar M; Kim WJ; Jin HR; Shin SH; Tuvshintur B; Yin GN; Song JS; Kwon MH; Lee SJ; Han JY; Kim SJ; Ryu JK; Suh JK
    J Sex Med; 2010 Oct; 7(10):3385-95. PubMed ID: 20233292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated intratunical injection of adenovirus expressing transforming growth factor-beta1 in a rat induces penile curvature with tunical fibrotic plaque: a useful model for the study of Peyronie's disease.
    Piao S; Ryu JK; Shin HY; Zhang L; Song SU; Han JY; Park SH; Kim JM; Kim IH; Kim SJ; Suh JK
    Int J Androl; 2008 Jun; 31(3):346-53. PubMed ID: 17651407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intratunical injection of rat-derived bone marrow mesenchymal stem cells prevents fibrosis and is associated with increased Smad7 expression in a rat model of Peyronie's disease.
    Wang W; Ding W; Zhang X; Wu S; Yu T; Cui X; Xie Y; Yang D; Lin C
    Stem Cell Res Ther; 2022 Jul; 13(1):390. PubMed ID: 35908015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.
    Valente EG; Vernet D; Ferrini MG; Qian A; Rajfer J; Gonzalez-Cadavid NF
    Nitric Oxide; 2003 Dec; 9(4):229-44. PubMed ID: 14996430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.
    Ferrini MG; Kovanecz I; Nolazco G; Rajfer J; Gonzalez-Cadavid NF
    BJU Int; 2006 Mar; 97(3):625-33. PubMed ID: 16469038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease.
    Gokce A; Abd Elmageed ZY; Lasker GF; Bouljihad M; Kim H; Trost LW; Kadowitz PJ; Abdel-Mageed AB; Sikka SC; Hellstrom WJ
    Andrology; 2014 Mar; 2(2):244-51. PubMed ID: 24574095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies.
    Paulis G; Brancato T
    Inflamm Allergy Drug Targets; 2012 Feb; 11(1):48-57. PubMed ID: 22309083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study.
    Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D
    BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IN-1130, a novel transforming growth factor-beta type I receptor kinase (activin receptor-like kinase 5) inhibitor, promotes regression of fibrotic plaque and corrects penile curvature in a rat model of Peyronie's disease.
    Ryu JK; Piao S; Shin HY; Choi MJ; Zhang LW; Jin HR; Kim WJ; Han JY; Hong SS; Park SH; Lee SJ; Kim IH; Lee CR; Kim DK; Mamura M; Kim SJ; Suh JK
    J Sex Med; 2009 May; 6(5):1284-96. PubMed ID: 19473283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microstructural disorders of tunica albuginea in patients affected by Peyronie's disease with or without erection dysfunction.
    Iacono F; Barra S; De Rosa G; Boscaino A; Lotti T
    J Urol; 1993 Dec; 150(6):1806-9. PubMed ID: 8230510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.